GRM2 and melanoma: The metabotropic glutamate receptor 2/3 (mGluR2/3) is expressed in MDSCs, and the mGluR2/3 antagonist LY341495 reduced the immune inhibitory function of MDSCs and further attenuated B16 melanoma growth [350].